

Electronic Acknowledgement Receipt

EFS ID:	1991143
Application Number:	10598840
International Application Number:	
Confirmation Number:	1117
Title of Invention:	3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
First Named Inventor/Applicant Name:	Justin S Bryans
Customer Number:	28523
Filer:	John Anthony Wichtowski/Madeline Deveran
Filer Authorized By:	John Anthony Wichtowski
Attorney Docket Number:	PC32229A
Receipt Date:	19-JUL-2007
Filing Date:	18-MAY-2007
Time Stamp:	17:21:48
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2001
Deposit Account	161445
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	WO2002010166.pdf	2808581	no	105
			167133c7b5c4808304cdd661d2dfd4ea221ec2bd		
Warnings:					
Information:					
2	Foreign Reference	WO2002028858.pdf	2814308	no	102
			1cc7ed35f412c4c3e0d222354ba0d8163897ef5f		
Warnings:					
Information:					
3	Foreign Reference	WO2002028859.pdf	2512176	no	106
			8d430c61d3b24698501e400f9750c0c2cd2df23a		
Warnings:					
Information:					
4	Foreign Reference	WO2002028865.pdf	2381221	no	95
			fe5af258d869a5d0fd9778d3488567dab8214d6b		
Warnings:					
Information:					
5	Foreign Reference	WO2002036593.pdf	1907400	no	66
			e124eece56bef92521f6ab2771b0b39078be0df8		
Warnings:					
Information:					
6	Foreign Reference	WO2002038563.pdf	2265160	no	81
			64d18efbf3feb8cfdb4e54b01bba793c2bcbde33		
Warnings:					
Information:					
7	Foreign Reference	WO2003000691.pdf	1495403	no	56
			3ba68c58d57da21b49f8d4189523ae7fd772e91b		
Warnings:					
Information:					
8	NPL Documents	COCO-AmFamilyPhys-1999.pdf	1426713	no	9
			9067d5e15f17451ca3d4da1777e2f7b6de260c13		
Warnings:					
Information:					
9	NPL Documents	Fininin-JPharmSci-1999.pdf	989564	no	4
			532b216d799dacabbc7c76769dcfa0469940ba93		

Warnings:					
Information:					
10	NPL Documents	Haleblian-JPharmSci1975.pdf	4599159	no	20
			08b1324f1ec31d74f8d2c0d1ab1f898a44030e89		
Warnings:					
Information:					
11	NPL Documents	Liang-ExpertOpinion981-2001.pdf	1447318	no	6
			2640850067a2d96b9c485becd960353dd056f127		
Warnings:					
Information:					
12	NPL Documents	Lieberman-PharmDosageVol1-1980.pdf	990695	no	79
			147507898e0fe28d1ae776bc3a94d599df70de2d		
Warnings:					
Information:					
13	NPL Documents	Schroeder-PedClinicsNA-1999.pdf	851366	no	14
			8deec0901d926439fa31c4e3c09fac91a39a477a		
Warnings:					
Information:					
14	NPL Documents	Verma-PharmTechOnLine-2001.pdf	3541326	no	14
			65962111bc8093f5e026de503d51cc1ef989760c		
Warnings:					
Information:					
15	NPL Documents	Wenk-EuropJPharma-2003.pdf	200567	no	6
			25b8124e5dbff42a35c23bce2d22ae34d268d716		
Warnings:					
Information:					
16	Information Disclosure Statement (IDS) Filed	iPC32229A-IDS.PDF	373074	no	6
			f7884ab39cf9c7b02f964558ff0dce20328dc10e		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
17	NPL Documents	BANWELL-JofOrgChem--2002.pdf	992740	no	4
			0967867fc32ce9cc02736bef7a92b83fe825ea97		
Warnings:					
Information:					

18	NPL Documents	Carter-ExpertOpinTherapeuticPatents--1998-1997.pdf	1322484 236777011feebbf49e420b52765359acdf04e8192	no	9
Warnings:					
Information:					
19	NPL Documents	Falch-EurJMedChem--1991.pdf	1553445 03b3dea0220149f54ca76b14f7b759d0e9da1ac6	no	9
Warnings:					
Information:					
20	NPL Documents	Rotella-JMedChem--2000.pdf	1545700 b72e1aaa8806d9f96aa765b5e25a08db60ca9a3a	no	7
Warnings:					
Information:					
21	Fee Worksheet (PTO-06)	fee-info.pdf	8246 0dde115dd3af94ebc16dc637a87b8c64f2f3f35b	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			36026646		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					